You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Ob…

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - prognosis, predictors and outcome
THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kojima T, Takahashi N, Kaneko A on behalf of Tsurumai Biologics Communication Registry (TBCR) , et al
THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan
Annals of the Rheumatic Diseases 2015;74:235-236.